This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Emerging Drugs and Targets for Multiple Sclerosis

Title Emerging Drugs and Targets for Multiple Sclerosis
Abstract

Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.

Apa Reference (2019). Emerging Drugs and Targets for Multiple Sclerosis. 10.1039/9781788016070
Doi 10.1039/9781788016070
Publication Date 18 Jun 2019
Publication Type Book / chapter
Researcher Ana Martínez
Ontology Drug Discovery and design, Development
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home